Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two New Sides Of Cubist: Antibiotics Maker Buys Both Optimer And Trius

This article was originally published in The Pink Sheet Daily

Executive Summary

The Boston-area company will no longer rely as heavily on the antibiotic Cubicin, once it takes out its partner on a second marketed drug and, separately, a clinical-stage antibiotics company. The deals give Cubist territorial rights to Optimer’s Dificid for C. diff and Trius’s tedizolid for Gram-positive infections for $535 million and $707 million, respectively, plus CVRs.

You may also be interested in...



Cubicin Becomes Blockbuster, As Cubist Passes on Adynxx Acquisition

The antibiotic developer said it will look to grow its portfolio of marketed products from three to four in 2014. Long-term it’s looking to do more acquisitions, perhaps with tax strategy in mind, but backed away from an option to acquire pain company Adynxx.

Cubist Pushes Trius Drug Forward As Cubicin Comes Up Short

The antibiotic drug maker is already making advantageous moves after closing one of its two most recent acquisitions, even as its highest-revenue product sees stalled growth.

Next Up For Cubist: A Future That Includes Optimer, Trius

Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel